此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ex Vivo Intraarterial Methylene Blue Injection Improve Nodal Staging Accuracy in Colorectal Cancer (MB)

2021年4月11日 更新者:St. Borbala Hospital

The Impact of ex Vivo Intra-arterial Methylene Blue Injection on Nodal Staging Accuracy and Survival in Colorectal Cancer.

Nodal staging holds both important prognostic and predictive value at colorectal cancer. Regional lymph nodes are located close to the primary tumor in the mesocolon / mesorectum. Current pathology and oncology standards require a separate examination of at least 12 lymph nodes each case to fulfill staging "accuracy" criteria.

In order to reach this number of lymph nodes, a precise surgical technique (total mesorectal excision or complete mesocolic excision), as well as a thorough pathological specimen work-up is needed.

The aim of the study is to investigate, if ex vivo intra-arterial methylene blue injection by the surgeon can help improving nodal harvesting effectivity of the pathologist, hence leading to a better staging and hopefully even to a better outcome in the long run.

In 2014-2015 two surgical centers randomised resected colorectal specimens in 1:1 ratio to methylene-blue injection arm and control (no injection) arm in a total of 200 consecutive cases. Both pathologic and oncologic treatment were led regardless of the injection, reports were just routinely saved in the routine medical documentation.

This retrospective study is designed to recall patient-related, surgery-related factors, as well as pathology reports including nodal staging from the medical databases. The investigators aim to find correlation between methylene blue "staining" and lymph node yield. In addition, the investigators plan to crossmatch methylene blue injection, as a process, with long term survival of the patients.

研究概览

地位

尚未招聘

详细说明

Background:

Colorectal Cancer is the second most common cause of death in Hungary. The most important prognostic and predictive factor of colorectal cancer is the stage of disease at the time of diagnosis. Precise staging, especially nodal staging is highly important for correct planning of oncotherapy, i.e. adjuvant chemotherapy. Nodal staging relies on the proper surgical removal of mesocolon/mesorectum belonging to the the affected colorectal segment, as well as on the thorough pathology work-up of the specimen.

Current quality standards require examination of a minimum of 12 lymph nodes in order to reliably report N0 stage.

Methylene-blue injection into the main supplying artery of the removed specimen is one of the simplest and most effective techniques described to aid pathologist in lymph node harvesting.

Technique of methylene blue injection:

First of all, surgeon need to en block remove the affected colorectal segment with its mesecolon/mesorectum. Then the surgeon isolates the main supplying artery and cannulated it with an appropriate-size canula.

Methylene blue solution (50 mg methylene blue diluted in in 30 ml saline) is prepared and injected into the freshly removed specimen via the canula until the blue solution appears on the cut edges of the specimen.

The specimen can be processed in a routine way (placed in 4% formaldehyde).

Aim of the study:

The aim is to investigate if the well described and in Western-European healthcare systems well tested technique (Methylene blue injection) can be effectively adapted in an overwhelmed, busy Eastern-European healthcare environment. (Other techniques, including pathology assistant are not affordable in this area.) Apart form testing diagnostic accuracy of the pathologist on specimens with and without methylene blue injection, the investigators would like to assess a potential survival benefit of the suspected improvement of staging effectivity.

Timing of the study:

Over a 20-month period of 2014 and 2015 two surgical centers in Hungary randomised their elective colorectal resection cases into interventional and control arms. Randomisation was performed with a 1:1 ratio at each site on 100-100 consecutive cases.

Further pathology work-up and reporting has been routinely performed without any specific effect on oncology follow-up or treatment. No specific data collection has been performed after the intervention.

This study aims to retrospectively select the 100-100 (total of 200) consecutive colorectal resection cases of the given time frame from the official hospital medical recording systems.

Pathology reports and other relevant patient clinical records will be collected and statistically assessed.

Ethical approval was requested and gained from the Medical Research Council, Hungary, for the retrospective analysis of patient data.

Statistical analysis:

Power analysis was performed to get the sufficient number of cases (200 cases in total).

Case Report Form The retrospectively included cases will be listed in a specific database on a safe medical server. Anthropometric, disease-specific, operation-specific and pathology report details will be extracted out of the official patient documentation system.

Patients will be included according to the known interventional interval and the operation type (elective colorectal resection). Cases in the database will be anonymized. No patient-identifying data will be recorded or given to the assessor of the study (statistician).

研究类型

介入性

注册 (预期的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Tatabánya、匈牙利、2800
        • St. Borbala Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Elective operation.
  • Colon or rectum resection performed.
  • Malignant colorectal condition.
  • Curative intent.

Exclusion Criteria:

  • Acute surgery performed
  • Final histology: benign
  • No other pathologic method (apart form Methylene Blue injection) used to improve lymph node yield

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Methylene blue
Methylene blue solution (50 mg in 30 ml of saline solution) was injected in the cannulated main supplying artery of the freshly removed specimen, ex vivo. Colorectal specimen was then processed in the routine pathological work-up way.
Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
无干预:Control
Colorectal specimens were processed in the routine pathological work-up way.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Total number of lymph nodes
大体时间:Within 4 weeks after operation (at pathology work-up)
Total number of lymph nodes examined by pathologist
Within 4 weeks after operation (at pathology work-up)
Positive lymph nodes
大体时间:Within 4 weeks after operation (at pathology work-up)
Number of positive lymph nodes found by pathologist
Within 4 weeks after operation (at pathology work-up)
Nodal staging accuracy
大体时间:Within 4 weeks after operation (at pathology work-up)
Minimum Nr of 12 lymph nodes examined if reported N stage is N0, or positive lymph node=s) found
Within 4 weeks after operation (at pathology work-up)
At least 12 lymph nodes harvested
大体时间:Within 4 weeks after operation (at pathology work-up)
Minimum Nr of 12 lymph nodes examined by pathologist
Within 4 weeks after operation (at pathology work-up)

次要结果测量

结果测量
措施说明
大体时间
Overall survival
大体时间:5 years (60 months) after operation
Overall survival after operation (in months)
5 years (60 months) after operation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Balazs Banky, PhD、St. Borbala Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年4月15日

初级完成 (预期的)

2021年7月15日

研究完成 (预期的)

2021年9月15日

研究注册日期

首次提交

2021年4月5日

首先提交符合 QC 标准的

2021年4月11日

首次发布 (实际的)

2021年4月13日

研究记录更新

最后更新发布 (实际的)

2021年4月13日

上次提交的符合 QC 标准的更新

2021年4月11日

最后验证

2021年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Methylene blue injection的临床试验

3
订阅